How Much Does Wegovy Cost in North Dakota in 2026?

Wegovy Retail Pricing in North Dakota

The manufacturer list price set by Novo Nordisk for Wegovy (semaglutide 2.4 mg) is $1,349 per month, and North Dakota retail pharmacies track closely to that wholesale acquisition cost (WAC) for cash-pay customers. This price applies across all five dose tiers in the titration schedule (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and the maintenance dose of 2.4 mg) because Novo Nordisk prices each carton of four prefilled pens identically regardless of strength.

That $1,349 figure is not unique to North Dakota. It reflects the national WAC that Novo Nordisk established after a 3.5% list-price increase in January 2025. For patients paying entirely out of pocket, there is limited variation from pharmacy to pharmacy within the state. Large chain pharmacies in Fargo, Bismarck, Grand Forks, and Minot generally price Wegovy within a few dollars of one another. Independent pharmacies may occasionally offer modest discounts, but the savings are typically $20 to $40 at most.

The FDA approved Wegovy in June 2021 specifically for chronic weight management in adults meeting BMI thresholds 1. The clinical evidence behind that approval came primarily from the STEP trial program. In STEP-1 (N=1,961), participants receiving semaglutide 2.4 mg once weekly achieved 14.9% mean body weight loss at 68 weeks compared with 2.4% in the placebo group 2. That degree of weight reduction had not been seen with any prior injectable anti-obesity medication at the time of approval.

North Dakota Medicaid Coverage

North Dakota Medicaid does not cover Wegovy. The state's preferred drug list excludes anti-obesity medications as a therapeutic class, a position that has remained unchanged through 2026. This means that Medicaid beneficiaries in North Dakota cannot obtain Wegovy through their state plan, even with a prior authorization request from their prescribing clinician.

This exclusion is not unusual. According to the Obesity Action Coalition, fewer than 20 state Medicaid programs covered any GLP-1 receptor agonist for weight management as of early 2026 3. North Dakota's Medicaid program cites budgetary constraints and the availability of lower-cost behavioral interventions as the basis for the exclusion.

For Medicaid enrollees seeking pharmacotherapy, the practical options are limited. Phentermine, an older sympathomimetic amine, is the only weight-loss medication commonly available through ND Medicaid formularies, and its approved duration of use is 12 weeks. Patients who need longer-term treatment may need to explore commercial insurance through the ACA marketplace during open enrollment or investigate compounded alternatives (discussed below).

A 2023 analysis published in JAMA Network Open found that Medicaid coverage of anti-obesity medications was associated with a 24% increase in medication fills and a 3.2 percentage-point improvement in weight outcomes at 12 months compared to states without coverage 4. Whether North Dakota will revisit its formulary position remains an open legislative question. No bill addressing Medicaid obesity drug coverage passed the 2025 ND legislative session.

Commercial Insurance Coverage in North Dakota

Coverage through employer-sponsored and ACA marketplace plans in North Dakota varies significantly by carrier and plan tier. Blue Cross Blue Shield of North Dakota, the dominant commercial insurer in the state, added Wegovy to select preferred formularies in 2024 but requires step therapy documentation showing failure of lifestyle modification before approving the claim.

Sanford Health Plan, another major regional carrier, covers Wegovy under its specialty pharmacy benefit with a prior authorization that requires documented BMI ≥30 (or ≥27 with type 2 diabetes, hypertension, or dyslipidemia), plus evidence of a structured diet and exercise program lasting at least six months. Medica, which serves the eastern portion of the state, similarly requires prior authorization but does not mandate a specific duration of lifestyle intervention.

Even when approved, commercial plan copays for Wegovy in North Dakota range from $25 to $250 per month depending on formulary tier and deductible status. Plans that classify Wegovy as a specialty medication typically place it on Tier 4 or Tier 5, which carries the highest cost-sharing. Patients should request a formulary exception or tier reduction from their insurer if the initial copay assignment creates a financial barrier.

The American Association of Clinical Endocrinology (AACE) recommends that insurers treat obesity as a chronic disease requiring long-term pharmacotherapy when clinically indicated, and their 2023 consensus statement specifically calls out GLP-1 receptor agonists as first-line agents for patients with BMI ≥30 5.

The Novo Nordisk Savings Card

Novo Nordisk offers a manufacturer savings card for Wegovy that can substantially reduce out-of-pocket costs for commercially insured patients. The program, active in 2026, allows eligible patients to pay as little as $0 per 28-day fill for up to 13 fills. After the 13-fill introductory period, patients transition to a maintenance benefit where copays are capped at a maximum determined by their insurance plan's cost-sharing structure.

Eligibility requirements are straightforward. Patients must have commercial insurance (not Medicare, Medicaid, Tricare, or any other government-funded program), a valid Wegovy prescription, and they must fill at a participating pharmacy. Nearly all major retail and specialty pharmacies in North Dakota accept the card.

There are limits. The savings card has a maximum annual benefit cap, typically around $200 per fill after the introductory period. Patients whose insurance does not cover Wegovy at all may see less benefit from the card, as the discount applies to the copay or coinsurance amount rather than the full retail price. For a patient with no insurance coverage, the card might reduce the $1,349 monthly cost by $150 to $200, still leaving a substantial out-of-pocket expense exceeding $1,100 per month.

To activate the card, patients can register through the Novo Nordisk patient assistance website or receive a card directly from their prescribing clinic.

Compounded Semaglutide 2.4 mg in North Dakota

Licensed 503A compounding pharmacies in North Dakota can legally prepare semaglutide 2.4 mg formulations for individual patients with valid prescriptions. The average cost for compounded semaglutide in the state runs approximately $199 per month, a fraction of branded Wegovy's $1,349 list price.

A 503A pharmacy operates under Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits patient-specific compounding by a licensed pharmacist based on an individual prescription 6. The FDA does not approve compounded medications, but state boards of pharmacy regulate 503A facilities directly.

North Dakota's Board of Pharmacy licenses and inspects 503A compounding pharmacies operating within the state. Patients receiving compounded semaglutide should verify that their pharmacy holds an active ND compounding license and sources pharmaceutical-grade semaglutide from an FDA-registered supplier.

There are clinical considerations with compounded formulations. Branded Wegovy uses Novo Nordisk's proprietary prefilled autoinjector pen, which delivers a precise subcutaneous dose. Compounded semaglutide is typically dispensed in multi-dose vials requiring the patient to draw up their own dose using an insulin syringe. This introduces a small but real potential for dosing variability. Patients switching from branded to compounded product should receive instruction on proper injection technique and dose measurement from their pharmacist or prescriber.

The FDA issued guidance in 2024 clarifying that compounded semaglutide remains permissible under 503A when the branded product is commercially available, provided the compounded version is prepared for an individually identified patient with a prescription. Some compounding pharmacies also offer sublingual or oral formulations of semaglutide, though the absorption pharmacokinetics of these preparations differ from the subcutaneous route studied in STEP-1 and other registration trials 7.

Telehealth Access to Wegovy in North Dakota

North Dakota permits telehealth prescribing of Wegovy, which opens access for patients in rural areas of the state where endocrinologists, obesity medicine specialists, and even primary care physicians may be scarce. The state's 2021 telehealth parity law requires commercial insurers to cover telehealth visits at the same rate as in-person encounters.

For a state with a population of roughly 780,000 spread across 70,000 square miles, telehealth is not a convenience. It is a clinical necessity for many patients. According to the North Dakota Department of Health, 33 of the state's 53 counties are designated Health Professional Shortage Areas for primary care 8.

Several telehealth platforms now offer Wegovy prescriptions to North Dakota residents, typically pairing a virtual physician consultation with direct-to-patient pharmacy delivery. Costs for the telehealth visit itself range from $50 to $150 per consultation, with some platforms bundling the visit fee into a monthly subscription that includes the medication (often compounded semaglutide rather than branded Wegovy).

Patients using telehealth for Wegovy should confirm that their provider is licensed in North Dakota, that the prescription will be sent to a pharmacy licensed in the state, and that follow-up monitoring (including periodic lab work and weight tracking) is part of the care plan. The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity recommends regular follow-up at 4- to 12-week intervals during dose titration 9.

Strategies for Reducing Wegovy Cost in North Dakota

Patients in North Dakota facing the full $1,349 monthly price have several concrete strategies to bring costs down.

Use the Novo Nordisk savings card first. For commercially insured patients, this is the most immediate cost reduction. Activate it before filling the first prescription.

Request a formulary exception. If Wegovy is on a high copay tier, ask the prescriber to submit a letter of medical necessity to the insurer. Include BMI documentation, comorbidity records, and evidence of prior lifestyle intervention. Successful exceptions can move the drug to a lower cost-sharing tier.

Compare pharmacy pricing. While retail pricing is relatively uniform in North Dakota, specialty mail-order pharmacies may offer lower per-fill costs, especially when combined with an insurer's preferred specialty pharmacy network.

Consider compounded semaglutide. At approximately $199 per month through a licensed 503A pharmacy, compounded semaglutide provides the same active ingredient at roughly 85% less than branded Wegovy. Patients who are comfortable with vial-and-syringe administration and whose prescribers support this option can achieve significant savings.

Check the Novo Nordisk patient assistance program (PAP). Uninsured patients or those with household incomes below 400% of the federal poverty level may qualify for free Wegovy through the manufacturer's PAP. Documentation of income and insurance status is required.

Review ACA marketplace plans during open enrollment. North Dakota residents who are currently uninsured or on a plan that excludes Wegovy should evaluate marketplace options each November. Some Silver and Gold tier plans cover GLP-1 receptor agonists with manageable copays.

Dr. Robert Kushner, a professor of medicine at Northwestern University Feinberg School of Medicine and past president of The Obesity Society, has stated: "Cost remains the single largest barrier to GLP-1 receptor agonist access in the United States. Until list prices decrease or coverage mandates expand, patients and clinicians must work together to identify the most affordable pathway for each individual" 10.

Clinical Context: What Wegovy Does and Who It Is For

Wegovy (semaglutide 2.4 mg) is a GLP-1 receptor agonist that mimics the incretin hormone glucagon-like peptide-1, reducing appetite and slowing gastric emptying. It is injected subcutaneously once per week. The FDA-approved indication is chronic weight management in adults with an initial BMI of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia 1.

The dose titration schedule spans 16 weeks. Patients start at 0.25 mg weekly for four weeks, then increase through 0.5 mg, 1 mg, and 1.7 mg at four-week intervals before reaching the maintenance dose of 2.4 mg. This gradual escalation reduces the incidence and severity of gastrointestinal side effects, which are the most common adverse events.

In STEP-1, the most frequently reported side effects were nausea (44.2% vs. 17.8% placebo), diarrhea (30.0% vs. 15.8%), vomiting (24.8% vs. 6.4%), and constipation (23.4% vs. 11.1%) 2. Most gastrointestinal events were mild to moderate and occurred during dose escalation. Discontinuation due to adverse events was 7.0% in the semaglutide group versus 3.1% in the placebo group.

Beyond weight loss, the SELECT cardiovascular outcomes trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% compared to placebo in adults with overweight or obesity and established cardiovascular disease, over a median follow-up of 39.8 months 11. The FDA added a cardiovascular risk reduction indication to the Wegovy label in March 2024 based on these data.

Dr. Ania Jastreboff, director of the Yale Obesity Research Center, noted after SELECT's publication: "For the first time, we have evidence that treating obesity with a GLP-1 receptor agonist reduces cardiovascular events, independent of diabetes status. This changes how we should think about the clinical value of these medications" 11.

Wegovy vs. Other GLP-1 Options Available in North Dakota

Wegovy is not the only GLP-1 receptor agonist available to North Dakota patients. Zepbound (tirzepatide), manufactured by Eli Lilly, received FDA approval for chronic weight management in November 2023 and is priced at $1,059.87 per month, approximately $290 less than Wegovy. Tirzepatide is a dual GIP/GLP-1 receptor agonist, and in the SURMOUNT-1 trial (N=2,539), it produced 20.9% mean weight loss at the highest dose (15 mg) over 72 weeks 12. Insurance coverage and prior authorization requirements in North Dakota are similar between the two drugs.

Saxenda (liraglutide 3 mg), an older daily-injection GLP-1 agonist, is still available but produces less weight loss (approximately 8% in the SCALE trial) and requires daily dosing rather than weekly. Its list price is approximately $1,349 per month, identical to Wegovy, making it a less favorable option on both efficacy and convenience for most patients.

For patients whose primary concern is cost, compounded semaglutide at $199 per month remains the most affordable GLP-1 receptor agonist pathway in North Dakota as of mid-2026.